Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Building towards Precision Oncology for Pancreatic Cancer: Real-World Challenges and Opportunities
Authors
Keywords
-
Journal
Genes
Volume 11, Issue 9, Pages 1098
Publisher
MDPI AG
Online
2020-09-21
DOI
10.3390/genes11091098
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des Myélodysplasies (GFM)
- (2020) Thomas Cluzeau et al. BLOOD
- CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
- (2020) Beatriz Salvador-Barbero et al. CANCER CELL
- Implementation of systematic genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).
- (2020) Matthew B. Yurgelun et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation
- (2020) Eileen M. O’Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN
- (2020) Keith T Flaherty et al. JNCI-Journal of the National Cancer Institute
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial
- (2020) Michael J Pishvaian et al. LANCET ONCOLOGY
- Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution
- (2020) Michelle Chan-Seng-Yue et al. NATURE GENETICS
- ATM Serine/Threonine Kinase and its Role in Pancreatic Risk
- (2020) Neha Nanda et al. Genes
- GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer
- (2020) Grainne M. O'Kane et al. CLINICAL CANCER RESEARCH
- Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection
- (2020) Wungki Park et al. CLINICAL CANCER RESEARCH
- NTRK gene fusions in bilio-pancreatic cancers.
- (2020) Anne Demols et al. JOURNAL OF CLINICAL ONCOLOGY
- CodeBreak 100: Phase I study of AMG 510, a novel KRASG12C inhibitor, in patients (pts) with advanced solid tumors other than non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
- (2020) David S. Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
- (2020) M. Patel et al. ANNALS OF ONCOLOGY
- Etiologic Index — A Case-Only Measure of BRCA1/2–Associated Cancer Risk
- (2020) Raymond Hughley et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination–deficient Pancreatic Cancer
- (2020) Yifan Wang et al. CLINICAL CANCER RESEARCH
- BI-3406, a potent and selective SOS1::KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition
- (2020) Marco H Hofmann et al. Cancer Discovery
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- Real-time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations that Might be Targeted with Existing Drugs or Used as Biomarkers
- (2019) Aatur D. Singhi et al. GASTROENTEROLOGY
- Ten-fold increase in genetic testing in pancreatic and metastatic prostate cancer with implementation of point of care (POC) testing.
- (2019) Heather Symecko et al. JOURNAL OF CLINICAL ONCOLOGY
- Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood
- (2019) Maryam A. L. Eissa et al. Clinical Epigenetics
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer
- (2019) S.B. Dreyer et al. CLINICAL ONCOLOGY
- Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis
- (2019) Francesco Natale et al. Clinical Epigenetics
- Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma
- (2019) Robert P. Jones et al. JAMA Surgery
- Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma
- (2019) Yao-Yu Hsieh et al. Genes
- Identifying patients with NTRK fusion cancer
- (2019) J P Solomon et al. ANNALS OF ONCOLOGY
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- OA02.02 Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
- (2019) R. Govindan et al. Journal of Thoracic Oncology
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Metastasis in Pancreatic Ductal Adenocarcinoma: Current Standing and Methodologies
- (2019) Marina Ayres Pereira et al. Genes
- Cell-Free DNA Methylation: The New Frontiers of Pancreatic Cancer Biomarkers’ Discovery
- (2019) Mariarita Brancaccio et al. Genes
- Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations
- (2018) Zishuo I. Hu et al. CLINICAL CANCER RESEARCH
- Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models
- (2018) Talia Golan et al. INTERNATIONAL JOURNAL OF CANCER
- Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer
- (2018) Chunling Hu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations
- (2018) Matteo Allegretti et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
- (2018) Maeve A Lowery et al. JNCI-Journal of the National Cancer Institute
- Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
- (2018) Luc Gailhouste et al. Cell Death & Disease
- Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes
- (2018) Gwen Lomberk et al. Nature Communications
- Organoid profiling identifies common responders to chemotherapy in pancreatic cancer
- (2018) Hervé Tiriac et al. Cancer Discovery
- Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms
- (2018) Maeve A Lowery et al. JNCI-Journal of the National Cancer Institute
- Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
- (2018) Rikke B. Holmgaard et al. Journal for ImmunoTherapy of Cancer
- Genetic assessment wait time indicators in the High Risk Ontario Breast Screening Program
- (2018) Andrea Eisen et al. Molecular Genetics & Genomic Medicine
- Clinical performance pilot using cognitive computing for clinical trial matching at Mayo Clinic.
- (2018) Jane Helgeson et al. JOURNAL OF CLINICAL ONCOLOGY
- Canadian profiling and targeted agent utilization trial (CAPTUR/PM.1): A phase II basket precision medicine trial.
- (2018) Tanya Skamene et al. JOURNAL OF CLINICAL ONCOLOGY
- Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
- (2018) Davide Melisi et al. BRITISH JOURNAL OF CANCER
- Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
- (2018) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
- (2018) Francesco Schettini et al. Frontiers in Oncology
- Guidelines for Validation of Next-Generation Sequencing–Based Oncology Panels
- (2017) Lawrence J. Jennings et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
- (2017) Marilyn M. Li et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
- (2017) John P Neoptolemos et al. LANCET
- A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer
- (2017) Paz Polak et al. NATURE GENETICS
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience
- (2017) Todd C. Knepper et al. ONCOLOGIST
- Enhancing Next‐Generation Sequencing‐Guided Cancer Care Through Cognitive Computing
- (2017) Nirali M. Patel et al. ONCOLOGIST
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor
- (2017) Jonathan M. Yingling et al. Oncotarget
- Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenografts
- (2017) Rémy Nicolle et al. Cell Reports
- Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma
- (2017) Ashton A. Connor et al. JAMA Oncology
- KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
- (2017) Jonas Cicenas et al. Cancers
- Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol
- (2016) F. Meric-Bernstam et al. ANNALS OF ONCOLOGY
- DNMT1 Inhibition Reprograms Pancreatic Cancer Stem Cells via Upregulation of the miR-17-92 Cluster
- (2016) S. Zagorac et al. CANCER RESEARCH
- GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer
- (2016) Paola Martinelli et al. GUT
- The role of neoantigens in response to immune checkpoint blockade
- (2016) Nadeem Riaz et al. INTERNATIONAL IMMUNOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Genomic analyses identify molecular subtypes of pancreatic cancer
- (2016) Peter Bailey et al. NATURE
- Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
- (2016) Y. Pommier et al. Science Translational Medicine
- Familial pancreatic cancer
- (2016) Gloria M. Petersen SEMINARS IN ONCOLOGY
- The Cell-Cycle Arrest and Apoptotic Functions of p53 in Tumor Initiation and Progression
- (2016) Jiandong Chen Cold Spring Harbor Perspectives in Medicine
- Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA
- (2016) Kasmintan A. Schrader et al. JAMA Oncology
- Current practices and guidelines for clinical next-generation sequencing oncology testing
- (2016) Samuel P. Strom et al. Cancer Biology & Medicine
- Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673
- (2015) Alexandra-Zoe Andrei et al. CANCER LETTERS
- KRAS as a Therapeutic Target
- (2015) F. McCormick CLINICAL CANCER RESEARCH
- Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec
- (2015) A.L. Smith et al. Current Oncology
- Prevalence of Germline Mutations in Cancer Predisposition Genes in Patients With Pancreatic Cancer
- (2015) Robert C. Grant et al. GASTROENTEROLOGY
- Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
- (2015) Spring Holter et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Whole genomes redefine the mutational landscape of pancreatic cancer
- (2015) Nicola Waddell et al. NATURE
- Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
- (2015) Richard A Moffitt et al. NATURE GENETICS
- All the World's a Stage: Facilitating Discovery Science and Improved Cancer Care through the Global Alliance for Genomics and Health
- (2015) M. Lawler et al. Cancer Discovery
- Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
- (2014) T Golan et al. BRITISH JOURNAL OF CANCER
- Cancers associated withBRCA1andBRCA2mutations other than breast and ovarian
- (2014) Jacqueline Mersch et al. CANCER
- The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings
- (2014) Maryam Shabihkhani et al. CLINICAL BIOCHEMISTRY
- More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling
- (2013) Aisha S. Sie et al. Familial Cancer
- Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
- (2013) Helmut Oettle et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical and molecular characterization of HER2 amplified-pancreatic cancer
- (2013) Angela Chou et al. Genome Medicine
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Effort Required in Eligibility Screening for Clinical Trials
- (2012) Lynne T. Penberthy et al. Journal of Oncology Practice
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
- (2011) Eric A Collisson et al. NATURE MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pancreatic cancerDNMT1expression and sensitivity toDNMT1inhibitors
- (2010) Ang Li et al. CANCER BIOLOGY & THERAPY
- Risk of Pancreatic Cancer in Families With Lynch Syndrome
- (2009) Fay Kastrinos JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Homologous recombination in DNA repair and DNA damage tolerance
- (2008) Xuan Li et al. CELL RESEARCH
- BRCAGermline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
- (2008) Cristina R. Ferrone et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas
- (2008) Seung-Mo Hong et al. MODERN PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search